ProCE Banner Activity

Targeting RET: Where We Are Today

Clinical Thought
Are you up to date on the latest information on targeting RET alterations in patients with NSCLC and other malignancies?

Released: July 25, 2019

Expiration: July 23, 2020

Share

Faculty

Justin F. Gainor

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Array BioPharma

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Foundation Medicine

Genentech TEXT Only

Loxo Oncology

Merck Oncology

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Justin F. Gainor, MD

Associate Professor
Department of Medicine
Harvard Medical School
Assistant in Medicine
Department of Medicine
Director, Center for Thoracic Cancers
Director of Targeted Immunotherapy
Massachusetts General Hospital
Boston, Massachusetts

Justin F. Gainor, MD, has disclosed that he has received funds for research support from Genentech, Novartis, and Takeda; funds for research support paid to his institution from Adaptimmune, Alexo, Array, Blueprint Medicines, Bristol-Myers Squibb, Jounce, Merck, Moderna, Novartis, and Tesaro; consulting fees from Agios, Amgen, Ariad/Takeda, Bristol-Myers Squibb, Blueprint Medicines, Genentech/Roche, Loxo Oncology, Oncorus, and Regeneron; and fees for non-CME/CE services from Incyte, Merck, Novartis, Pfizer, Roche, and Theravance; and that his spouse receives salary from Ironwood.